Archive


Category: BRAF

  • Novartis bags FDA okay for BRAF-positive tumour combination

    Novartis’ two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body. The so-called “tumour-agnostic” indication for BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) covers patients aged six and over […]